Prescribery recently announced its partnership with KnippeRx to provide Vyleesi, a prescription medication developed by Palatin Technologies, Inc. to treat premenopausal women with hypoactive sexual desire disorder (HSDD).
Approved by the FDA in 2019, Vyleesi is a self-administered shot injected into a spot on the abdomen or the top of the thigh before anticipated sexual activity. HSDD, characterized by lack of sexual pleasure and desire, affects as many as 10% of women. While HSDD can be the result of underlying physical or emotional ailments, Vyleesi is designed to remedy HSDD when there is no ascertainable underlying cause.
Vyleesi is only the second prescription treatment for HSDD to be approved by the FDA for women. Unlike the other pharmacological option, Vyleesi is taken as needed rather than requiring a daily dosage in the form of a pill. An overwhelming majority of the women who participated in clinical trials requested a one-year extension of Vyleesi.
The FDA identified female sexual dysfunction as 1 of 20 high-priority health issues that needed to be focused on beginning in 2012. Vyleesi is an important step forward in addressing this priority.
Administration and Side Effects of Vyleesi
Patients self-administer a dose of Vyleesi by injection at least 45 minutes before anticipated sexual activity. Individuals should not inject more than 1 dose of Vyleesi within a 24-hour period and should not exceed 8 doses of Vyleesi within a month.
The most common side effects associated with the use of Vyleesi are mild and include reaction at the injection site, flushing, headache, vomiting, tingling, nasal congestion, and dizziness. Women who experience uncontrolled hypertension or cardiovascular disease should not use Vyleesi.
Possible Serious Side Effects From Vyleesi Include:
- A temporary elevation in blood pressure and a decreased heart rate.
- A darkening of the skin in certain areas including the face, the gums, and the breasts.
- Severe nausea
About Prescribery
Prescribery provides an innovative digital solution that enables patients and doctors to expedite direct-to-consumer prescription delivery. Through a seamless and HIPPA-compliant process, patients are able to have their prescriptions delivered to their homes after a simple prequalification assessment and a telemedicine appointment with a physician licensed in their state.
